| Literature DB >> 30559785 |
Irum Butool1, Shabnam Nazir2, Maryam Afridi3, Syed Majid Shah4.
Abstract
BACKGROUND &Entities:
Keywords: Ambulatory elderly; PRISCUS list; Potential prescribing omissions; Potentially inappropriate medication; STOPP/START criteria
Year: 2018 PMID: 30559785 PMCID: PMC6290224 DOI: 10.12669/pjms.346.14928
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Patients’ characteristics.
| Data Collection: Prescriptions of reimbursed medications: | |
| Items of data included in each collection: | 300 prescriptions |
| Mean age±SD (years old) | 60.16 (±8.165) |
| Range of individual age | 50-87 |
| Men (% of the elderly patients in each population groups) | 138 (46%) |
| Women (% of the elderly patientsin each population groups) | 162 (54%) |
| Age groups: | |
| 46-60 years old | 189 |
| 61-75 years old | 95 |
| >76years old | 16 |
| No of medications in each collection of data±SD | 1262 (1.353%) |
| Total number of diagnosis | 441 |
| Frequency of types of diagnosis in each collection of data: | |
| Cardiovascular (CVS) | 46 (10.43%) |
| Neuropsychiatric | 13 (2.95%) |
| Rheumatologic | 90 (20.41 %) |
| Diabetes | 21 (4.76%) |
| Gastrointestinal (GIT) | 18 (4.081%) |
| Respiratory | 22 (5%) |
| Urologic | 56 (12.7%) |
| Ophthalmologic | 04 (0.907%) |
| Other | 41 (9.3%) |
Types of Potentially Inappropriate Medications (PIM).
| Medications sample analyzed: | |
| –Total number of medications prescribed to the ambulatory elderly: | 1262 |
| –Total number of PIMs in each sample of medications prescribed: | 146 |
| Subtype – PIM: | |
| Misprescribed – PIM: | 104 (71.23%) |
| Underprescribed– PIM: | 28 (19.18%) |
| Overprescribed– PIM: | 14 (9.59%) |
Potentially inappropriate medications identified in the ambulatory elderlypharmacotherapy.
| Subtype – PIM Reference | no. of examples | % of the respective | % of 146 |
|---|---|---|---|
| Criteria: reason to avoid | of subtype-PIM | subtype-PIM | PIM |
| Misprescribed – PIM | 104 | ||
| NSAIDs as chronic analgesics in myalgia, backache and rheumatoid diseases: | 49 | 47.11% | 33.56% |
| PRISCUS list –analgesics, anti-inflammatory drugs: | |||
| – very high risk of gastrointestinal hemorrhage, ulceration, or perforation, which may be fatal | |||
| – indometacin: central nervous disturbances | |||
| – phenylbutazone: blood dyscrasia | |||
| – etoricoxib: cardiovascular contraindications | |||
| STOPP tool –musculoskeletal system | 15 | 14.42% | 10.27% |
| – NSAID with moderate-severe hypertension | 14 | ||
| – Long-term NSAID or colchicine for chronic treatment of gout where there is no contraindication to allopurinol | 01 | ||
| Benzodiazepines: | 12 | 11.54% | 8.22% |
| PRISCUS list - sedatives, hypnotic agents: | |||
| Long, short and intermediate acting: | |||
| – risk of falling with risk of hip fracture | |||
| – prolonged reaction times | |||
| – psychiatric reactions | |||
| – cognitive impairment | |||
| PRISCUS list - (diphenhydramine) | 03 | 2.88% | 2.05% |
| – anticholinergic effects | |||
| – dizziness | |||
| – ECG changes | |||
| Anticholinergic drugs (Antihistamines) | 02 | 1.92% | 1.37% |
| PRISCUS list- Anticholinergic drugs: | |||
| – anticholinergic side effects (e.g., constipation, dry mouth) | |||
| – impaired cognitive performance | |||
| – ECG changes (prolonged QT) | |||
| STOPP tool –CNS and Psychotic Drugs | 03 | 2.88% | 2.05% |
| fluazepam, nitrazepam, chlorazepate and benzodia- zepines with long-acting metabolites e.g. diazepam | 02 | ||
| –Prolonged use (> 1 week) of first generation antihistamines i.e. diphenhydramine, cyclizine, chlorpheniramine, promethazine | 01 | ||
| Antipsychotics: | 01 | 0.96% | 0.68% |
| PRISCUS- neuroleptic drugs: | |||
| – anticholinergic and extrapyramidal side effects | |||
| – clozapine: increased risk of agranulocytosis and myocarditis | |||
| STOPP tool – CNS and Psychotropic Drugs | 01 | 0.96% | 0.68% |
| –neuroleptics as long-term hypnotics | 01 | ||
| Antiemetic drugs: | 02 | 1.92% | 1.37% |
| PRISCUS list - Tricyclic antidepressants: | |||
| – peripheral and central anticholinergic side effects | |||
| – cognitive deficit – increased risk of falling | |||
| STOPP tool – CNS and Psychotropic Drugs | 02 | 1.92% | 1.37% |
| PRISCUS list – (dimenhydramine) | |||
| – anticholinergic side effects | |||
| Anti-dementia drugs, vasodilators, circulation-promoting agents: | 01 | 0.96% | 0.68% |
| PRISCUS list – (piracetam) | |||
| – no proof of efficacy, unfavorable risk/ benefit profile | |||
| Duplicate drug classes (two concurrent NSAIDs) | 10 | 9.61% | 6.85% |
| Endocrine System: | 01 | 0.96% | 0.68% |
| Underprescribed – PIM | 28 | ||
| Underprescribing statins in coronary, cardiovascular and cerebrovascular diseases: | 13 | 46.43% | 8.90% |
| START tool - Cardiovascular system: | |||
| –Statin therapy | |||
| Underprescribing of statins in diabetes mellitus: | 01 | 3.57% | 0.68% |
| START tool - Endocrine system: | |||
| –Statin therapy in diabetes mellitus if additional cardiovascular risk factors present | |||
| Underprescribing of antihypertensive therapy where systolic blood pressure consistently>160 mmHg | 03 | 10.71% | 2.05% |
| Underprescribing of B-2 agonists or anticholinergic agents in asthma: | 01 | 3.57% | 0.68% |
| Underprescribing antidepressants in the presence of mild-moderate depressive symptoms lasting at least 3months: | 02 | 7.14% | 1.37% |
| UnderprescribingCa and Vitamin D supplements in patients with known osteoporosis: | 03 | 10.71% | 2.05% |
| Underprescribing DMARD with moderate-severe rheumatoid disease lasting > 12 weeks | 02 | 7.14% | 1.37% |
| Underprescribing metformin with type 2 diabetes: | 01 | 3.57% | 0.68% |
| Underprescribing ACE inhibitor or Angiotensin Receptor Blocker in diabetes with nephropathy: | 01 | 3.57% | 0.68% |
| Underprescribing L-DOPA in idiopathic Parkinson’s disease: | 01 | 3.57% | 0.68% |
| Overprescribed – PIM: | 14 | 100% | 9.59% |
| Overprescribing NSAIDs | |||
| – very high risk of gastrointestinal hemorrhage, ulceration, or perforation, which may be fatal | 14 | ||